Michael Lilly to Fusion Proteins, bcr-abl
This is a "connection" page, showing publications Michael Lilly has written about Fusion Proteins, bcr-abl.
Connection Strength
0.173
-
Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. Am J Hematol. 2010 Mar; 85(3):164-70.
Score: 0.091
-
Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J Clin Invest. 2008 Sep; 118(9):3038-50.
Score: 0.082